MX2016005808A - Composiciones y metodos para el tratamiento de enfermedades virales con moduladores de pde4. - Google Patents

Composiciones y metodos para el tratamiento de enfermedades virales con moduladores de pde4.

Info

Publication number
MX2016005808A
MX2016005808A MX2016005808A MX2016005808A MX2016005808A MX 2016005808 A MX2016005808 A MX 2016005808A MX 2016005808 A MX2016005808 A MX 2016005808A MX 2016005808 A MX2016005808 A MX 2016005808A MX 2016005808 A MX2016005808 A MX 2016005808A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treatment
viral diseases
pde4 modulators
Prior art date
Application number
MX2016005808A
Other languages
English (en)
Inventor
Jerome B Zeldis
Vikram Khetani
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2016005808A publication Critical patent/MX2016005808A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen los métodos de tratamiento y/o prevención de enfermedades y trastornos virales, como aquellos que se mejoran mediante la inhibición de PDE4.
MX2016005808A 2013-11-06 2014-11-05 Composiciones y metodos para el tratamiento de enfermedades virales con moduladores de pde4. MX2016005808A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900489P 2013-11-06 2013-11-06
PCT/US2014/064047 WO2015069711A1 (en) 2013-11-06 2014-11-05 Compositions and methods for the treatment of viral diseases with pde4 modulators

Publications (1)

Publication Number Publication Date
MX2016005808A true MX2016005808A (es) 2016-07-18

Family

ID=51999519

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005808A MX2016005808A (es) 2013-11-06 2014-11-05 Composiciones y metodos para el tratamiento de enfermedades virales con moduladores de pde4.

Country Status (14)

Country Link
US (1) US20160289188A1 (es)
EP (1) EP3065778A1 (es)
JP (1) JP2016540041A (es)
KR (1) KR20160068981A (es)
CN (1) CN105873611A (es)
AR (1) AR099283A1 (es)
AU (1) AU2014346877A1 (es)
CA (1) CA2929539A1 (es)
EA (1) EA201690937A1 (es)
IL (1) IL245511A0 (es)
MX (1) MX2016005808A (es)
PH (1) PH12016500824A1 (es)
SG (1) SG11201603469UA (es)
WO (1) WO2015069711A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605914A (en) * 1993-07-02 1997-02-25 Celgene Corporation Imides
NZ540546A (en) * 2002-11-18 2008-03-28 Celgene Corp Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
CN1452982A (zh) * 2003-06-25 2003-11-05 上海兴康医药研究开发有限公司 用于预防sars的利巴韦林黏膜给药制剂及制备方法
MXPA06012279A (es) * 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar.
WO2007139150A1 (ja) * 2006-05-30 2007-12-06 The University Of Tokushima ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤
ES2424214T3 (es) * 2007-08-27 2013-09-30 Siga Technologies, Inc. Medicamentos antivirales para el tratamiento de una infección por Arenavirus
US20100080807A1 (en) * 2008-09-26 2010-04-01 National Taiwan University Methods and Compositions for Treating Viral Hemorrhagic Fever
US20100297033A1 (en) * 2009-05-21 2010-11-25 Mcleay Matthew T Megaribavirin alone or combination of other antiviral, antioxidant and a perflubron emulsion for treatment of viral disease
MX341050B (es) * 2010-04-07 2016-08-05 Celgene Corp * Metodos para tratar infeccion viral respiratoria.
WO2012118599A1 (en) * 2011-02-28 2012-09-07 Emory University C-abl tyrosine kinase inhibitors useful for inhibiting filovirus replication

Also Published As

Publication number Publication date
AR099283A1 (es) 2016-07-13
JP2016540041A (ja) 2016-12-22
PH12016500824A1 (en) 2016-06-13
AU2014346877A1 (en) 2016-05-26
SG11201603469UA (en) 2016-05-30
CN105873611A (zh) 2016-08-17
CA2929539A1 (en) 2015-05-14
EP3065778A1 (en) 2016-09-14
WO2015069711A1 (en) 2015-05-14
KR20160068981A (ko) 2016-06-15
IL245511A0 (en) 2016-06-30
US20160289188A1 (en) 2016-10-06
EA201690937A1 (ru) 2017-02-28

Similar Documents

Publication Publication Date Title
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
MX2018003472A (es) Moduladores de la expresion de kras.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2020011749A (es) Composiciones y metodos para modular la expresion de pkk.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX2021008281A (es) Estimuladores de guanilato ciclasa soluble (sgc).
IN2015DN00438A (es)
HK1216175A1 (zh) 治療性化合物和組合物
WO2015073587A3 (en) Synthetic membrane-receiver complexes
EP3662903A3 (en) Combination therapies
IN2015DN01156A (es)
NZ755605A (en) Compositions for modulating tau expression
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
EA201591278A1 (ru) Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы
MX2015001250A (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
IN2014DN06792A (es)
HK1213888A1 (zh) 治療化合物和組合物以及其作為pkm2調節劑的用途
TW201713333A (en) Methods of treating a neurodegenerative disease
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
GEAP201814286A (en) Halogenated quinazolinthf-amines as pde1 inhibitors